<DOC>
	<DOCNO>NCT01336023</DOCNO>
	<brief_summary>This trial conduct globally . The aim trial compare efficacy safety insulin degludec/liraglutide ( IDegLira ) versus insulin degludec ( IDeg ) liraglutide ( Lira ) subject type 2 diabetes . Subjects continue pre-trial treatment metformin metformin + pioglitazone throughout entire trial .</brief_summary>
	<brief_title>Dual Action Liraglutide Insulin Degludec Type 2 Diabetes : A Trial Comparing Efficacy Safety Insulin Degludec/Liraglutide , Insulin Degludec Liraglutide Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Subjects type 2 diabetes HbA1c 7.010.0 % ( inclusive ) aim median HbA1c 8.3 % . Accordingly , approximately 50 % randomised subject HbA1c 8.3 % , remain subject randomise must HbA1c equal 8.3 % , approximately 50 % randomised subject HbA1c equal 8.3 % , remain subject randomise must HbA1c 8.3 % Male female , age 18 year ( Taiwan : 20 year site 653 Taiwan : Taichung Veterans General Hospital ) Subjects stable dose 12 OADs ( metformin [ least 1500 mg max tolerate dose ] metformin [ least 1500 mg max tolerate dose ] + pioglitazone [ least 30 mg ] ) least 90 day prior screen Body Mass Index ( BMI ) maximum 40 kg/m^2 Treatment insulin ( except shortterm treatment due intercurrent illness discretion Investigator ) Treatment GLP1 ( glucagonlike peptide1 ) receptor agonist ( eg exenatide , liraglutide ) , sulphonylurea dipeptidyl peptidase 4 ( DPP4 ) inhibitor within 90 day prior trial Impaired liver function , define alanine aminotransferese ( ALAT ) least 2.5 time Upper Normal Range ( UNR ) ( one retest analyse central laboratory within week first sample take permit result last sample conclusive ) Impaired renal function define serumcreatinine least 133 mcmol/l ( least 1.5 mg/dl ) males least 125 mcmol/l ( least 1.4 ) female , allow accord local contraindication metformin ( one retest analyse central laboratory within week first sample take permit result last sample conclusive ) Screening calcitonin least 50 ng/L Subjects personal family history medullary thyroid carcinoma ( MTC ) multiple endocrine neoplasia type 2 ( MEN 2 ) Cardiac disorder define : congestive heart failure ( NYHA class IIIIV ) , diagnosis unstable angina pectoris , cerebral stroke and/or myocardial infarction within last 12 month plan coronary , carotid peripheral artery revascularisation procedure Severe uncontrolled treat untreated hypertension ( systolic blood pressure least 180 mm Hg diastolic blood pressure least 100 mm Hg ) Acute treatment require proliferative retinopathy maculopathy ( macular oedema ) History chronic pancreatitis idiopathic acute pancreatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>